Biomarkers and ImmuneScores in lung cancer: predictive insights for immunotherapy and combination treatment strategies

Lung cancer remains the leading cause of cancer related deaths worldwide. Immunotherapy and combination therapies, involving chemotherapy, radiotherapy, and tumor anti-angiogenesis therapy, have shown promising clinical results and are expected to become a key approach in the future management of lung cancer. However, due to immune resistance, immunotherapy remains highly effective in only a subset of patients, while many others either do not respond initially or develop resistance over time. Moreover, immune-related adverse events induced by immunotherapy, further complicate treatment outcomes and prognosis. Immune-related biomarkers and ImmuneScores have driven the development of personalized immunotherapy strategies for lung cancer, and they can aid in predicting immune resistance, and forecasting immune-related adverse events (irAEs). This review summarizes the prognosis value of immune-related biomarkers and ImmuneScores in immunotherapy and combination therapies for lung cancer. The aim is to provide a foundation for personalized treatment and management of lung cancer, while offering guidance for future research directions in immunotherapy.

• Publication year

  2025

• Venue

  Biological Procedures Online

• Publication date

  2025-07-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1186/s12575-025-00287-0PMID 40640703PMCID 12243280
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer.

  2025cited by this paper
• Efficacy of first-line chemotherapy combined with immunotherapy or anti-angiogenic therapy in advanced KRAS-mutant non-small cell lung cancer

  2025cited by this paper
• Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial

  2025cited by this paper
• A diagnostic model for assessing the risk of osteoporosis in patients with rheumatoid arthritis based on bone turnover markers

  2025cited by this paper
• Homologous recombination deficiency status predicts response to immunotherapy‐based treatment in non‐small cell lung cancer patients

  2024cited by this paper
• First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a China-based cost-effectiveness analysis

  2024cited by this paper
• Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review

  2024cited by this paper
• Lung cancer treatment: 20 years of progress.

  2024cited by this paper
• Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer.

  2024cited by this paper
• Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer

  2024cited by this paper
• Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC

  2024cited by this paper
• A tumor cornification and immune-infiltration-based scheme for anti-PD-1 plus chemotherapy response in advanced squamous cell lung carcinoma.

  2024cited by this paper
• Ultrasensitive plasma-based monitoring of tumor burden using machine learning-guided signal enrichment

  2024cited by this paper
• Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours

  2024cited by this paper
• The combination of tumor mutational burden and T‐cell receptor repertoire predicts the response to immunotherapy in patients with advanced non–small cell lung cancer

  2024cited by this paper
• Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis

  2024cited by this paper
• Decision model for durable clinical benefit from front- or late-line immunotherapy alone or with chemotherapy in non-small cell lung cancer.

  2024cited by this paper
• Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer.

  2024cited by this paper
• Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities.

  2024cited by this paper
• Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer

  2024cited by this paper
• Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system

  2024cited by this paper
• Pan-cancer analysis implicates novel insights of lactate metabolism into immunotherapy response prediction and survival prognostication

  2024cited by this paper
• HOXC9 characterizes a suppressive tumor immune microenvironment and integration with multiple immune biomarkers predicts response to PD-1 blockade plus chemotherapy in lung adenocarcinoma

  2024cited by this paper
• CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.

  2024cited by this paper
• Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition.

  2024cited by this paper
• LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation.

  2024cited by this paper
• Immunotherapy for lung cancer.

  2024cited by this paper
• Correlation of lung immune prognostic index with the efficacy of immune checkpoint inhibitors in Chinese patients with advanced non-small cell lung cancer

  2024cited by this paper
• The extracellular matrix as hallmark of cancer and metastasis: From biomechanics to therapeutic targets

  2024cited by this paper
• The Clinical Analysis of Checkpoint Inhibitor Pneumonitis with Different Severities in Lung Cancer Patients: A Retrospective Study

  2024cited by this paper
• An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers

  2023cited by this paper
• Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma

  2023cited by this paper
• Immunotherapy of MSI Cancer: Facts and Hopes.

  2023influential reference
• Identification of exosome protein panels as predictive biomarkers for non-small cell lung cancer

  2023cited by this paper
• Combining Radiation Therapy with Immune Checkpoint Blockade for the Treatment of Small Cell Lung Cancer.

  2023cited by this paper
• Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis

  2023cited by this paper
• Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population

  2023cited by this paper
• Clinical prediction models of rheumatoid arthritis and its complications: focus on cardiovascular disease and interstitial lung disease

  2023cited by this paper
• Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era

  2023cited by this paper
• The global burden of lung cancer: current status and future trends

  2023cited by this paper
• Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.

  2023cited by this paper
• HLA-I evolutionary divergence confers response to PD-1 blockade plus chemotherapy in untreated advanced non-small-cell lung cancer.

  2023cited by this paper
• Machine learning-based risk model incorporating tumor immune and stromal contexture predicts cancer prognosis and immunotherapy efficacy

  2023cited by this paper
• Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis

  2023cited by this paper
• Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy

  2023cited by this paper
• Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer

  2023cited by this paper
• A prognostic and immunotherapeutic predictive model based on the cell-originated characterization of tumor microenvironment in lung adenocarcinoma

  2023cited by this paper
• Immunotherapy-based combinations in metastatic NSCLC.

  2023cited by this paper
• Classification of Tumor Immune Microenvironment (TIME) According to PD-L1 Expression and Immune Infiltration Predicts Response to Immunotherapy plus Chemotherapy in Advanced NSCLC Patients.

  2023cited by this paper
• Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing

  2023cited by this paper
• Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

  2023cited by this paper
• An Individualized Approach to Comorbidities in Lung Cancer.

  2023cited by this paper
• Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis

  2022cited by this paper
• On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial

  2022cited by this paper
• Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism

  2022cited by this paper
• EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment

  2022cited by this paper
• Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities

  2022cited by this paper
• Construction of a predictive model for immunotherapy efficacy in lung squamous cell carcinoma based on the degree of tumor-infiltrating immune cells and molecular typing

  2022cited by this paper
• Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review

  2022cited by this paper
• Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors.

  2022cited by this paper
• Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC.

  2022cited by this paper
• Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer: a pooled analysis.

  2022cited by this paper
• LATPS, a novel prognostic signature based on tumor microenvironment of lung adenocarcinoma to better predict survival and immunotherapy response

  2022cited by this paper
• Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade.

  2022cited by this paper
• Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden

  2022cited by this paper
• Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.

  2021cited by this paper
• Radiation-activated secretory proteins of Scgb1a1+ club cells increase the efficacy of immune checkpoint blockade in lung cancer

  2021cited by this paper
• Toward personalized treatment approaches for non-small-cell lung cancer

  2021cited by this paper
• Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial

  2021cited by this paper
• Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges

  2021cited by this paper
• Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small-cell lung cancer: results from a randomized, double-blind, phase 3 trial (ORIENT-12).

  2021cited by this paper
• Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.

  2021cited by this paper
• Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.

  2021cited by this paper
• Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.

  2020cited by this paper
• Analysis of Lung Adenocarcinoma Subtypes Based on Immune Signatures Identifies Clinical Implications for Cancer Therapy

  2020cited by this paper
• Radiation Therapy and the In Situ Vaccination Approach

  2020cited by this paper
• Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.

  2020cited by this paper
• Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors.

  2020cited by this paper
• Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer.

  2020influential reference
• Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action

  2020cited by this paper
• Radiation and In-Situ Tumor Vaccination.

  2020cited by this paper
• The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy

  2020cited by this paper
• The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort

  2019influential reference
• Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction

  2019cited by this paper
• Prognostic Value of the Advanced Lung Cancer Inflammation Index in Patients with Lung Cancer: A Meta-Analysis

  2019cited by this paper
• Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients.

  2019influential reference
• Tertiary lymphoid structures in the era of cancer immunotherapy

  2019cited by this paper
• Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.

  2019cited by this paper
• Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

  2018cited by this paper
• Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018

  2018cited by this paper
• Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer

  2018cited by this paper
• Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

  2018cited by this paper
• International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.

  2018cited by this paper
• CTLA-4: a moving target in immunotherapy.

  2018cited by this paper
• Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells

  2018cited by this paper
• Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer

  2018cited by this paper
• Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer

  2017influential reference
• Immunotherapy in Lung Cancer.

  2017cited by this paper
• The diverse functions of the PD1 inhibitory pathway

  2017cited by this paper
• Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).

  2017cited by this paper

• Inflammatory–Molecular Clusters as Predictors of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer

  2026cites this paper
• Pharmacological strategies to overcome immune checkpoint inhibitor resistance in non-small cell lung cancer

  2026cites this paper
• Terminally exhausted CD8+ T cells in solid tumors: biology, biomarker potential and translational tools for precision oncology

  2026cites this paper
• Genomic alterations and their correlation with metabolic-related genes in lung cancer.

  2026cites this paper
• Circulating microRNAs and Plasma Gelsolin as Biomarkers of Sepsis: Molecular Insights and Prospects for Precision Medicine

  2025cites this paper
• DKK1 Overexpression in Lung Adenocarcinoma: Prognostic Implications, Immune Microenvironment Correlates, and Regulatory Network Characterization

  2025cites this paper